Floatz logo

syn608

HRR Deficiency

Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the HRR Deficiency cohort.

Asset / SponsorPhaseRating
Olaparib
Eisbach Bio GmbH
Phase 1/2CC
Trastuzumab Deruxtecan
Eisbach Bio GmbH
Phase 1/2CC
Eis-12656
Eisbach Bio GmbH
Phase 1/2CC
syn818
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Phase 1CC

Same molecule, other indications

syn608 is also rated in:

Advanced Solid CancerDormant
CC
Indicative ·
41 / 100
View asset →
BRCA MutationDormant
CC
Indicative ·
41 / 100
View asset →
Metastatic Solid TumorDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →